{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:28:51Z","timestamp":1792621731482,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"27","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 2013, the European Heart Rhythm Association (EHRA) published a Practical Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) (Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625\u2013651; Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094\u20132106). The document received widespread interest, not only from cardiologists but also from neurologists, geriatricians, and general practitioners, as became evident from the distribution of &amp;gt;350 000 copies of its pocket version (the EHRA Key Message Booklet) world-wide. Since 2013, numerous new studies have appeared on different aspects of NOAC therapy in AF patients. Therefore, EHRA updated the Practical Guide, including new information but also providing balanced guiding in the many areas where prospective data are still lacking. The outline of the original guide that addressed 15 clinical scenarios has been preserved, but all chapters have been rewritten. Main changes in the Update comprise a discussion on the definition of \u2018non-valvular AF\u2019 and eligibility for NOAC therapy, inclusion of finalized information on the recently approved edoxaban, tailored dosing information dependent on concomitant drugs, and\/or clinical characteristics, an expanded chapter on neurologic scenarios (ischaemic stroke or intracranial haemorrhage under NOAC), an updated anticoagulation card and more specifics on start-up and follow-up issues. There are also many new flow charts, like on appropriate switching between anticoagulants (VKA to NOAC or vice versa), default scenarios for acute management of coronary interventions, step-down schemes for long-term combined antiplatelet-anticoagulant management in coronary heart disease, management of bleeding, and cardioversion under NOAC therapy. The Updated Guide is available in full in EP Europace (Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, Advisors. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467\u20131507), while additional resources can be found at the related ESC\/EHRA website (www.NOACforAF.eu).<\/jats:p>","DOI":"10.1093\/eurheartj\/ehw058","type":"journal-article","created":{"date-parts":[[2016,6,9]],"date-time":"2016-06-09T21:58:25Z","timestamp":1465509505000},"page":"2137-2149","source":"Crossref","is-referenced-by-count":83,"title":["Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary"],"prefix":"10.1093","volume":"38","author":[{"given":"Hein","family":"Heidbuchel","sequence":"first","affiliation":[{"name":"1Hasselt University and Heart Center, Stadsomvaart 11, Hasselt 3500, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Verhamme","sequence":"additional","affiliation":[{"name":"2Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Alings","sequence":"additional","affiliation":[{"name":"3Department of Cardiology, Amphia Ziekenhuis, Breda, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Antz","sequence":"additional","affiliation":[{"name":"4Department of Cardiology, Klinikum Oldenburg, Oldenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Christoph","family":"Diener","sequence":"additional","affiliation":[{"name":"5Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Hacke","sequence":"additional","affiliation":[{"name":"6Department of Neurology, Ruprecht Karls Universit\u00e4t, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Oldgren","sequence":"additional","affiliation":[{"name":"7Department of Medical Sciences, Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Sinnaeve","sequence":"additional","affiliation":[{"name":"2Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. John","family":"Camm","sequence":"additional","affiliation":[{"name":"8Clinical Cardiology, St George's University, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[{"name":"9University of Birmingham Centre for Cardiovascular Sciences, Birmingham, UK"},{"name":"10Department of Cardiology and Angiology, University of M\u00fcnster, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ESC Scientific Document Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azhar","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Heinrich-Nols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"M\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Schwertfeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"van Eickels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Richard-Lordereau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"UK","given":"Gregory","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"(Taiwan)","given":"Chern-En","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"(USA)","given":"Jonathan","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"(Serbia)","given":"Tatjana","family":"Potpara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"(France)","given":"Laurent","family":"Fauchier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"(UK)","given":"Deirdre","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"(Brazil)","given":"Alvaro","family":"Avezum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"(Denmark)","given":"Torben","family":"Bjerregaard Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"(Italy)","given":"Guiseppe","family":"Boriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"(Spain)","given":"Vanessa","family":"Roldan-Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"(Turkey)","given":"Bulent","family":"Gorenek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,6,9]]},"reference":[{"key":"2026080920445962200_ehw058C1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/europace\/eut083","article-title":"European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation","volume":"15","author":"Heidbuchel","year":"2013","journal-title":"Europace"},{"key":"2026080920445962200_ehw058C2","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1093\/eurheartj\/eht134","article-title":"EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"34","author":"Heidbuchel","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080920445962200_ehw058C3","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"2026080920445962200_ehw058C4","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/europace\/euq350","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"12","author":"Camm","year":"2010","journal-title":"Europace"},{"key":"2026080920445962200_ehw058C5","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"2026080920445962200_ehw058C6","first-page":"e199","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation"},{"key":"2026080920445962200_ehw058C7","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban compared with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE trial","volume":"132","author":"Avezum","year":"2015","journal-title":"Circulation"},{"issue":"(12 Suppl.)","key":"2026080920445962200_ehw058C8","doi-asserted-by":"crossref","first-page":"A325","DOI":"10.1016\/S0735-1097(14)60325-9","article-title":"Comparison of dabigatran versus warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY\u00ae trial","volume":"63","author":"Ezekowitz","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080920445962200_ehw058C9","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","article-title":"Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial","volume":"35","author":"Breithardt","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080920445962200_ehw058C10","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","article-title":"What is \u2018valvular\u2019 atrial fibrillation? A reappraisal","volume":"35","author":"De Caterina","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080920445962200_ehw058C11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"issue":"(suppl.)","key":"2026080920445962200_ehw058C12","first-page":"685","article-title":"Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial","volume":"33","author":"Granger","year":"2012","journal-title":"Eur Heart J"},{"key":"2026080920445962200_ehw058C13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ahj.2014.09.006","article-title":"Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"169","author":"Granger","year":"2015","journal-title":"Am Heart J"},{"key":"2026080920445962200_ehw058C14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jacc.2014.05.028","article-title":"Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial","volume":"64","author":"Ruff","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080920445962200_ehw058C15","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1093\/eurheartj\/eht557","article-title":"Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry","volume":"35","author":"Beyer-Westendorf","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080920445962200_ehw058C16","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/europace\/euv190","article-title":"Antithrombotic management in patients undergoing electrophysiological procedures: a European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS)","volume":"17","author":"Sticherling","year":"2015","journal-title":"Europace"},{"key":"2026080920445962200_ehw058C17","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1056\/NEJMoa1302946","article-title":"Pacemaker or defibrillator surgery without interruption of anticoagulation","volume":"368","author":"Birnie","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080920445962200_ehw058C18","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.amjcard.2012.12.046","article-title":"Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices","volume":"111","author":"Rowley","year":"2013","journal-title":"Am J Cardiol"},{"key":"2026080920445962200_ehw058C19","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/jce.12214","article-title":"Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin","volume":"24","author":"Jennings","year":"2013","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026080920445962200_ehw058C20","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/europace\/eus027","article-title":"2012 HRS\/EHRA\/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design","volume":"14","author":"Calkins","year":"2012","journal-title":"EP Europace"},{"key":"2026080920445962200_ehw058C21","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1161\/CIRCULATIONAHA.113.006426","article-title":"periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the role of coumadin in preventing thromboembolism in atrial fibrillation (AF) patients undergoing catheter ablation (COMPARE) randomized trial","volume":"129","author":"Di Biase","year":"2014","journal-title":"Circulation"},{"key":"2026080920445962200_ehw058C22","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080920445962200_ehw058C23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1160\/TH14-08-0712","article-title":"Reversal of dabigatran anticoagulation ex vivo: porcine study comparing prothrombin complex concentrates and idarucizumab","volume":"113","author":"Honickel","year":"2015","journal-title":"Thromb Haemost"},{"key":"2026080920445962200_ehw058C24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080920445962200_ehw058C25","first-page":"381","article-title":"Recent advances in antidotes for direct oral anticoagulants: their arrival is imminent","volume":"30","author":"Lauw","year":"2014","journal-title":"Can J Cardiol"},{"key":"2026080920445962200_ehw058C26","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N Engl J Med"},{"key":"2026080920445962200_ehw058C27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCULATIONAHA.114.013445","article-title":"Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate","volume":"131","author":"Zahir","year":"2015","journal-title":"Circulation"},{"key":"2026080920445962200_ehw058C28","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"key":"2026080920445962200_ehw058C29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1182\/blood.V124.21.345.345","article-title":"Reversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in healthy subjects","volume":"124","author":"Perlstein","year":"2014","journal-title":"Blood"},{"issue":"(Suppl. 1)","key":"2026080920445962200_ehw058C30","first-page":"148","article-title":"Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate","volume":"93","author":"van Ryn","year":"2008","journal-title":"Haematologica"},{"key":"2026080920445962200_ehw058C31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1160\/TH11-01-0052","article-title":"Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis","volume":"106","author":"Dentali","year":"2011","journal-title":"Thromb Haemost"},{"key":"2026080920445962200_ehw058C32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"2026080920445962200_ehw058C33","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation"},{"key":"2026080920445962200_ehw058C34","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2013.09.062","article-title":"Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)","volume":"63","author":"Flaker","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080920445962200_ehw058C35","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1016\/j.jacc.2013.02.025","article-title":"Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial","volume":"61","author":"Piccini","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080920445962200_ehw058C36","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","article-title":"Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation","volume":"35","author":"Cappato","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080920445962200_ehw058C37","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"2026080920445962200_ehw058C38","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"2026080920445962200_ehw058C39","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"2026080920445962200_ehw058C40","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1378\/chest.14-2099","article-title":"Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study","volume":"147","author":"Bronnum Nielsen","year":"2015","journal-title":"Chest"},{"key":"2026080920445962200_ehw058C41","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/CIRCULATIONAHA.115.015735","article-title":"Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a Nationwide Cohort Study","volume":"132","author":"Nielsen","year":"2015","journal-title":"Circulation"},{"key":"2026080920445962200_ehw058C42","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/S0140-6736(99)05388-X","article-title":"Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators","volume":"353","author":"Taylor","year":"1999","journal-title":"Lancet"},{"key":"2026080920445962200_ehw058C43","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/europace\/euv124","article-title":"Non-vitamin K antagonist oral anticoagulants (NOAC): considerations on once- vs. twice-daily regimens and their potential impact on medication adherence","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/27\/2137\/70580056\/eurheartj_38_27_2137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/27\/2137\/70580056\/eurheartj_38_27_2137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:45:06Z","timestamp":1786322706000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/38\/27\/2137\/2996308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,9]]},"references-count":43,"journal-issue":{"issue":"27","published-online":{"date-parts":[[2016,6,9]]},"published-print":{"date-parts":[[2017,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehw058","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726413857.793520485","asserted-by":"object"}]},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7,14]]},"published":{"date-parts":[[2016,6,9]]}}}